Poxel Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • POXEL

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.16
  • (As of Friday Closing)

Poxel General Information

Description

Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

Contact Information

Website
www.poxelpharma.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Tour Part Dieu, 129 rue Servient
  • 69007 Lyon
  • France
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
PAR
Vertical(s)
Life Sciences
Corporate Office
  • Tour Part Dieu, 129 rue Servient
  • 69007 Lyon
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Poxel Stock Performance

As of 13-Nov-2026, Poxel’s stock price is $0.16. Its current market cap is $10.8M with 67M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.16 $0.17 $0.15 - $0.57 $10.8M 67M 659K -$0.28

Poxel Financials Summary

As of 30-Jun-2025, Poxel has a trailing 12-month revenue of $8.32M.

In Thousands,
USD 		TTM 30-Jun-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 78,346 49,817 57,432 49,088
Revenue 8,323 7,181 2,144 709
EBITDA (10,301) (13,157) (13,172) (28,426)
Net Income (14,852) (19,808) (37,970) (33,012)
Total Assets 5,864 15,541 5,331 37,227
Total Debt 17,171 20,968 44,520 41,687
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Poxel Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Poxel‘s full profile, request access.

Request a free trial

Poxel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, in
Pharmaceuticals
Lyon, France
5 As of 2025

Lexington, MA
 

Grand Rapids, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Poxel Competitors (89)

One of Poxel’s 89 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Cirius Therapeutics Venture Capital-Backed Grand Rapids, MI
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Peloton Therapeutics Formerly VC-backed Dallas, TX
Johnson&Johnson Innovative Medicine Venture Capital-Backed Raritan, NJ
You’re viewing 5 of 89 competitors. Get the full list »

Poxel Patents

  • 323

    Total Documents Applications and Grants

  • Total Patents Families

  • 200

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Poxel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2023532950-A Crystalline form of deuterium-enriched pioglitazone Pending 30-Jun-2020
AU-2021300003-A1 Crystalline forms of deuterium-enriched pioglitazone Pending 30-Jun-2020
CA-3184123-A1 Crystalline forms of deuterium-enriched pioglitazone Pending 30-Jun-2020
EP-4003514-A1 Crystalline forms of deuterium-enriched pioglitazone Active 30-Jun-2020
EP-4003514-B1 Crystalline forms of deuterium-enriched pioglitazone Active 30-Jun-2020 C07D417/12
To view Poxel’s complete patent history, request access »

Poxel Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Poxel Investments (1)

Poxel’s most recent deal was a Corporate Asset Purchase with DeuteRx (DRX-065 Drug) for . The deal was made on 30-Aug-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
DeuteRx (DRX-065 Drug) 30-Aug-2018 Corporate Asset Purchase Buildings and Property
To view Poxel’s complete investments history, request access »

Poxel ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Poxel’s complete esg history, request access »

Poxel FAQs

  • When was Poxel founded?

    Poxel was founded in 2009.

  • Where is Poxel headquartered?

    Poxel is headquartered in Lyon, France.

  • What is the size of Poxel?

    Poxel has 5 total employees.

  • What industry is Poxel in?

    Poxel’s primary industry is Pharmaceuticals.

  • Is Poxel a private or public company?

    Poxel is a Public company.

  • What is Poxel’s stock symbol?

    The ticker symbol for Poxel is POXEL.

  • What is the current stock price of Poxel?

    As of 13-Nov-2026 the stock price of Poxel is $0.16.

  • What is the current market cap of Poxel?

    The current market capitalization of Poxel is $10.8M.

  • What is Poxel’s current revenue?

    The trailing twelve month revenue for Poxel is $8.32M.

  • Who are Poxel’s competitors?

    Dicerna Pharmaceuticals, Cirius Therapeutics, Renova Therapeutics, Peloton Therapeutics, and Johnson&Johnson Innovative Medicine are some of the 89 competitors of Poxel.

  • What is Poxel’s annual earnings per share (EPS)?

    Poxel’s EPS for 12 months was -$0.28.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process